Navigation Links
Vasogen Provides Update on ACCLAIM II Program
Date:3/3/2008

MISSISSAUGA, ON, March 3 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today provided an update on ACCLAIM II, a clinical trial which is being planned to support an application for U.S. market approval of the Celacade(TM) System for the treatment of patients with New York Heart Association (NYHA) Class II heart failure.

The Company announced in December that the FDA was examining its internal jurisdiction over Vasogen's Celacade System in the context of a newly issued draft guidance document to assess whether this document was relevant to Celacade. Previously, the FDA's Center for Devices and Radiological Health (CDRH) acted as lead reviewer of Celacade, with input from the Center for Biologics Evaluation and Research (CBER). The FDA has confirmed that Celacade will remain regulated as a medical device; however, CBER will be the lead reviewer of the Celacade technology, with CDRH providing input. The transition process from CDRH to CBER is now complete.

As part of the transition, on February 29, CDRH communicated to the Company that they now disagree with the use of a Bayesian approach because of a concern with recruiting a heterogeneous study population between ACCLAIM and ACCLAIM II. This is contrary to the FDA's original communication to Vasogen recommending a Bayesian study design, and, as part of its ongoing informal dialogue, the Company plans to provide the FDA with its position regarding the ACCLAIM II study population.

"The FDA's comments with respect to utilizing a Bayesian approach for the design of ACCLAIM II are surprising," commented Chris Waddick, President and CEO of Vasogen. "Our immediate focus will be to engage in discussions with the FDA to clarify their position on the proposed ACCL
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... ended June 30, 2014.  Biorem,s complete 2014 second quarter financial statements and ... Summary:Three-months ended June 30, , Six-months ended June ... , 2013 , 2014 , 2013 ... , 9,195 Gross profit , 56 , ...
(Date:8/22/2014)... published today (August 22nd), in the scientific journal ... Neuroscience Programme establish the effect of serotonin on ... genetic and optical techniques., "Serotonin is a small ... range of brain functions, from the control of ... emotional behaviours, This neurotransmitter is also popularly thought ...
(Date:8/22/2014)... investigated for application as catalysts, sensors, drug ... in photonics and molecular electronics. Gaining knowledge ... physical and chemical properties, has been challenging. ... demonstrated that high-resolution electron microscopy can be ... which all gold atoms are observed. The ...
(Date:8/22/2014)... The Global and China Diabetes Drugs Industry ... state of the Diabetes Drug industry in Global and ... the industry, including definitions, applications and industry chain structure. ... provided with a focus on history, developments, trends and ... international and Chinese situation is also offered. , The ...
Breaking Biology Technology:Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3From happiness to pain: Understanding serotonin's function 2A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 3
... , MISSOULA, Mont., June 24 VEGA PROMOTIONAL SYSTEMS, ... owned subsidiary, Natural Fuels Industries, it is planning to ... to produce alternative energy from organic waste. , ... "America,s Best Places For Alternative Energy," the abundance of ...
... BOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex ... that the company has reached an agreement with the ... protocol assessment process (SPA) on an amendment to the ... its lead product candidate targeting castrate resistant prostate cancer ...
... Higher Percentage of Patients Have Preventative Testing , ... Advice Networks , the nation,s leading provider of ... Healthy Advice educational programs, 16.9 percent more ... percent more patients had colonoscopies (colon cancer screening) compared ...
Cached Biology Technology:Natural Fuels Industries Eyes 'Biomass Rich' Georgia for Production Facility 2Natural Fuels Industries Eyes 'Biomass Rich' Georgia for Production Facility 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 5Healthy Advice Networks Announces Improved Patient Outcomes in Physicians' Offices with Healthy Advice Programs 2
(Date:8/21/2014)... previously unknown process for harvesting energy and producing oxygen ... State University scientist has discovered. The discovery lays the ... harvesting energy from the Sun, and understanding dense blooms ... lakes worldwide. A paper describing the discovery will be ... the journal Science on 21 August 2014. ...
(Date:8/21/2014)... Israel Deaconess Medical Center (BIDMC ) are among the ... Minds 2014," a comprehensive list compiled by ... science metrics and research performance analysis. , ... performing and publishing work that their peers recognized as ... a Thomson Reuters statement. Researchers were identified based on ...
(Date:8/21/2014)... study recently published in the journal Carcinogenesis ... new role for the protein adenomatous polyposis coli (APC) ... cancer-related deaths in the U.S. , Lead author Kristi ... and co-leader of the Cancer Biology program at the ... her career trying to understand the various activities of ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3
... The citrus disease Huanglongbing (HLB), meaning "yellow shoot ... in English-speaking countries, is the most destructive disease ... tools and management strategies are desired to control ... phosphorus deficiency as a contributing factor in symptom ...
... species of scorpion, Vaejovis brysoni, was found in the ... the same group also inhabits this mountain range, making this ... species distributed on the same mountain. The study was published ... . These mountains overlook the city of Tucson, Arizona. ...
... Sloan Foundation is pleased to announce the selection of ... Sloan Research Fellowships for 2013. , Awarded annually ... and scholars whose achievements and potential identify them as ... "The Sloan Research Fellows are the best of the ...
Cached Biology News:Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 2Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 3Sloan Foundation announces 2013 Sloan Research Fellows 2
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
Biology Products: